

## Intra-Cellular Therapies to Present at Upcoming Investor Conferences

February 7, 2018

NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the following upcoming investor conferences.

- LEERINK Partners 7th Annual Global Healthcare Conference taking place in New York, NY: Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present on Wednesday, February 14, 2018 at 9:30 am ET.
- 2018 RBC Capital Markets Global Healthcare Conference taking place in New York, NY: Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present on Wednesday, February 21, 2018 at 11:30 am ET.

The live and archived webcasts can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at [www.intracellulartherapies.com](http://www.intracellulartherapies.com). Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

### About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson's disease.

#### Contact:

Juan Sanchez, M.D.  
Vice President  
Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc.  
Phone: 646-440-9333

Burns McClellan, Inc.  
Lisa Burns  
Justin Jackson (Media)  
Email: [jjackson@burnsmc.com](mailto:jjackson@burnsmc.com)  
Phone: 212-213-0006

[Primary Logo](#)

Source: Intra-Cellular Therapies Inc.